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Abstract
Background: The use of anti-malarial drug combinations with artemisinin, or with one of its derivatives, is now
widely recommended to overcome drug resistance in falciparum malaria. Fixed-dose combination of artemisinin
and naphthoquine is a new generation artemisinin combination therapy (ACT) offered as a single dose therapy. The
aim of the study was to assess the therapeutic efficacy, safety and tolerability of three dosage schedules of
fixed-dose combination of artemisinin (125 mg) and naphthoquine (50 mg) for treating uncomplicated Plasmodium
falciparum malaria among adolescents and adults in Calabar, South-east Nigeria.
Method: A total of 121 patients aged ≥15 years with uncomplicated P. falciparum malaria were enrolled and
randomly assigned to three dosage schedules: (A) 700 mg (four tablets) single dose; (B) 700 mg 12-hourly x two
doses; and (C) 1,400 mg (eight tablets) single dose. Patients were observed for 28 days, with clinical, parasitological,
and haematological assessments.
Results: A total of 108 patients completed the study. The overall 28-day cure rate was 88.9%. Day 28-cure rates of
the three dosage schedules were 85.3%, 93.1% and 88.9% for Group A, B and C respectively. Adverse events were
few and mild, the commonest being weakness and headache; there was no serious adverse event.
Conclusion: Concerns for emergence of parasite resistance due to the use of artemisinin-naphthoquine as single
dose regimen is likely to compromise the usefulness of this potentially important combination treatment. A robust
multi-centre trial is recommended to evaluate a three-day regimen with potentials to achieve high cure rates while
minimizing the risk of emergence of resistant parasite strains.
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Background
Malaria remains a major public health problem in Nigeria
accounting for as much as 30% childhood deaths and
11% maternal mortality in Nigeria [1]. High levels of
Plasmodium falciparum resistance to chloroquine [2]
and sulphadoxine-pyrimethamine [3] preparations led to
the worsening of the malaria situation in the country and
prompted drug therapeutic efficacy tests (DTET) on
artemisinin-based combinations in the country. The
results of the DTET informed the change in the malaria
treatment policy in 2005 [4].
Nigeria adopted artemisinin based combination ther-
apy (ACT) as the treatment of choice for uncomplicated
plasmodium falciparum malaria. The goal of combin-
ation therapy is to increase effectiveness of available
antimalarial drugs and delay the emergence and spread
of drug resistance [5,6]. The strategy is supported
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empirically by the success of combination therapy in
treating tuberculosis and human immunodeficiency virus
infections, and by mathematical models [7]. By using
two or more drugs with independent mechanisms of ac-
tion, it is believed that mutations that confer resistance
to each drug will only rarely co-exist in the same para-
site, thereby minimizing the incidence of resistant strains
of the parasite. ACT is, therefore, expected to improve
treatment cure rate and delay the emergence of drug re-
sistance [8].
A fixed dose combination of artemisinin-naphthoquine
(Arco™) developed by Kunming Pharmaceuticals Corpor-
ation (KPC), China was tested in this study. The drug is
administered orally as a single dose treatment for uncom-
plicated falciparum malaria. In addition to the high cure
rate of 97% recorded in two earlier reports by Chinese
investigators [9,10], this treatment regimen is likely to
have the advantage of a high rate of patient compliance
given the simple dosage schedule. Naphthoquine is
rapidly absorbed reaching peak plasma concentration
2-4 hours after administration [11]. It is slow in ac-
tion while artemisinin is rapid in action thus artemisinin
immediately starts the antimalarial action by rapidly
killing all the malaria-causing Plasmodium parasites
in the body (about 97% of the parasites in 24 hours)
while naphthoquine which stays longer (half life 41–
57 hours) starts its own anti-malarial action late, but
continues its action long after the elimination of artemi-
sinin [12].
The aim of this study was to assess the therapeutic
efficacy, safety and tolerability of fixed dose combination
of artemisinin-naphthoquine for the treatment of un-
complicated falciparum malaria among adolescents
and adults in Nigeria. Separate trials in younger children




The study was conducted from 6th March 2006 to 19th
August 2006 in a Primary Health Centre (PHC) in Ikot
Ansa, Calabar of Cross River State. The health centre is
located in a semi-urban community with holoendemic
P. falciparum transmission. The level of Plasmodium
falciparum resistance to chloroquine and sulphadoxine-
pyrimethamine is high [1-3].
Study design and patients enrolment
The study was an open-label, non-comparative thera-
peutic efficacy clinical trial carried out following the
standard WHO protocol for in vivo efficacy [13]. Patients
attending out-patient clinic at study site with symptoms
suggestive of malaria were screened for the following
inclusion criteria: (1) mono infection of uncomplicated
P. falciparum malaria with a diagnosis confirmed by a
positive blood smear with asexual forms of P. falcip-
arum; (2) residence in the study area throughout dur-
ation of follow up; (3) age ≥15 years; (4) history of
fever within the past 24 hours or axillary temperature
≥37.5°C; (5) parasite density of 500–200,000 asexual
parasites/μl; (6) absence of signs of severe malaria as
defined by World Health Organization’s criteria [14])
or any other life-threatening condition; and (7) signed
informed consent (by patient or from parents/guardian
if less than 18 years). Exclusion criteria were: (1) preg-
nancy; (2) history of allergy to any of the drug compo-
nents; (3) severe malnutrition; (4) severe anaemia
(haematocrit < 15%); (5) history of having taken an
anti-malarial in the past two weeks and (6) presence of
any other severe illness or any “danger sign” such as in-
ability to sit, stand up, drink, persistent vomiting, con-
vulsions, lethargy or unconsciousness.
Sample size calculation
The sample size was determined based on the WHO
standard protocol for non-comparative therapeutic effi-
cacy studies [13]. Assuming an anticipated population
proportion of clinical failure (p) of 10%, confidence level
of 95% and study precision (d) of 10% point, the calcu-
lated sample size for each arm was 35. An adjustment of
20% for follow-up losses and withdrawals was made as
recommended in the WHO protocol for studies with
follow-up periods > 14 days. The adjusted sample size
per arm was 42 participants. The aim was to enrol a
minimum of 42 patients per arm or retain at least 35 at
completion of follow-up.
Ethical considerations
The study was approved by the national regulatory au-
thority in Nigeria. Ethical approval was received from
the Ethics Committee of University of Calabar Teaching
Hospital prior to onset of study. A written informed
consent was obtained from each patient (or the parent/
legal guardians if < 18 years) prior to enrolment.
Treatment
Patients were randomly assigned to one of three dosage
scheduled of fixed-dose combination of artemisinin-
naphthoquine as follows: Group A received four tablets
as a single dose; Group B received four tablets twice at
12 hours interval (total of eight tablets); Group C
received eight tablets as a single dose. The allocation se-
quence was generated by simple balloting and concealed
in serially numbered, opaque, sealed envelopes. This was
opened by the study nurse at the point of drug adminis-
tration following completion of consent and all clinical
procedures. All the treatments were given in the health
facility under direct observation of the study personnel.
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Drugs were given with water and after patient had a
meal. Tepid sponging, exposure and administration of
paracetamol were used to reduce high fever. Patients
were observed for about 30 minutes after administration
of drug and treatment was repeated once if patient vom-
ited within 30 minutes of drug administration. Patients
that vomited a second time were excluded from the trial
and treated as severe illness. All patients were treated as
outpatient.
Clinical and laboratory assessment
Clinical examination including axillary temperature
measurement, body weight and height were recorded on
day of enrolment (day 0). During each follow-up visit,
clinical examination including temperature was per-
formed. Parasitological examination (thin and thick
blood films) were performed on enrolment using Giemsa
and performed on each follow up visits. Parasite density
was enumerated using thick film as described by Shute
[15]. Blood films were considered negative if no parasites
were seen in 100 oil-immersion fields in a thick blood
film. Routine biochemical and haematological laboratory
measurements were done on a fraction (25%) of the en-
rolled patients.
Follow-up
Follow-up visits were scheduled on days 1, 2, 3, 7, 14, 21
and 28. Packed cell volume (PCV) was estimated on day
zero and repeated on days 14 and 28 for all patients
using blood sample collected in a heparinized capillary
tube, spun for 5 minutes at 5,000 rpm with micro-
haematocrit centrifuge and read with micro-haematocrit
reader. Participants that did not return on schedule for
follow up were visited at home the same day by study
field staff.
Outcome measures
Outcomes were defined based on the WHO guidelines
for assessing therapeutic efficacy [13]. The 28-day cure
rate i.e. Adequate Clinical and Parasitological Response
(ACPR) was the absence of parasitaemia on day 28 with-
out previously meeting criteria for ETF, LCF or LPF was
taken as the primary efficacy endpoint. Secondary out-
come measures were Early Treatment Failure (ETF – dan-
ger signs or complicated malaria or failure to adequately
respond to therapy days 0–3 or parasitaemia on day 2
higher than day 0; or parasitaemia on dya 3 ≥ 25% of day
0 values); Late Clinical Failure (LCF – development of
danger signs or severe malaria and parasitaemia after day
3 or presence of parasitaemia and fever on days 4 – 28
without previously meeting criteria for ETF); Late Para-
sitological Failure (LPF – asymptomatic parasitaemia on
day 28 without previously meeting criteria for ETF or
LCF); the change in the mean packed cell volume from
day 0 to day 28, fever and parasite clearance time, safety
and tolerability of the treatment regimen. Safety and tol-
erability assessment consisted of monitoring and record-
ing of all adverse events (AEs – an unfavourable or
unintended signs or symptoms or illness that develops or
worsens during the period of observation in the study)
and Serious Adverse Events (SAEs). SAE was defined as
any untoward event that results in death, is life threaten-
ing, requires inpatient hospitalization or results in per-
sistent or significant disability/incapacity.
Quality control
Clinical and laboratory procedures were subjected to in-
ternal quality control. There was no external monitor
for this study. However, the trial was audited by officials
from the regulatory body in Nigeria; the National
Agency for Food and Drug Administration and Control
(NAFDAC). Standard operating procedures based on the
principles of good clinical practice were prepared for
measurement of height, weight, temperature, collection
of blood samples and calculation of parasite counts.
Malaria parasites were counted by two microscopists in-
dependently and the average count was taken as the final
count. Where there was a marked difference in count
(>25%) between study team microscopists, such slides
were sent to an external field microscopist to confirm
the count. The external microscopist also randomly
selected and reviewed 10% of all the slides read by study
team microscopists. Haematology and biochemical tests
were conducted in the laboratories of the University of
Calabar Teaching Hospital with quality control measures
in place.
Statistical analysis
Data generated were recorded in a log book, and indi-
vidual patients’ case report files were double – entered
and analysed first in EPI Info Version 6 and later using
SPSS (version 11.0.1). Arithmetic and geometric means
as well as standard deviation were calculated for baseline
characteristics. One-way ANOVA was used to test for
statistical significance and p-values less than 0.05 were
considered to be statistically significant. Both intention-
to-treat and per protocol analyses were presented for the
main outcomes.
Results
General characteristics and flow of trial participants
A total of 992 persons were screened; 348 (35.1%) were
males and 644 (64.9%) females. One hundred and
twenty-one (121) patients with uncomplicated malaria
who fulfilled the inclusion criteria were enrolled: 36 to
Group A; 35 to Group B and 50 to Group C (Figure 1).
The commonest reasons for exclusion were low pa-
rasite density and recent treatment with anti-malarials.
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Figure 1 Flow diagram of trial participants.
Table 1 Enrolment and baseline data of trial participants
Participants characteristics Group A Group B Group C *p-value
Number enrolled 36 35 50
Female 27 19 28
Male 9 16 22
Mean Age in years (±SD) 29.2 32.8 31.6 0.554
(±12.4) (±14.3) (±13.2)
Mean Temperature in degrees°C (±SD) 36.6 37.1 37.0 0.439
(±0.88) (±0.94) (±0.96)
Mean Weight in Kg (±SD) 60.4 65.5 65.2 0.272
(±11.5) (±15.3) (±11.6)
Mean Height in Cm (±SD) 157.8 160.5 163.3 0.108
(±18.4) (±7.8) (±7.3)
Mean Day 0 Haematocrit (±SD) 36.9 38.5 39.3 0.104
(±3.6) (±5.1) (±4.8)
Geomean Day 0 parasite density/uL (95% CI) 1273 1160 1624 0.514
(924. - 1754) (842. - 1599.) (1179–2238)
*ANOVA.
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Study participants had similar characteristics at baseline
(Table 1).
Treatment outcome
Table 2 summarizes the treatment outcome for the
primary and secondary efficacy endpoints. The overall
28-day cure rate (not confirmed by PCR) was 88.9%.
The cure rate for the different treatment groups were
85.3%, 93.1% and 88.9% for Group A, Group B and
Group C respectively. A total of 12 (9.9%) patients had
late parasitological failure (LPF): 5 in Group A and C
respectively and 1 in Group B. There was no early
treatment failure (ETF). Table 2 also shows that seven
patients (5.8%) were lost to follow up and while six per-
sons (4.9%) withdrew from the study with overall attrition
rate of 10.7%.
Parasite and fever clearance
Mean fever clearance time was 24.7 hours (Figure 2).
Mean parasite clearance time in this study was 44.8
hours for all study arms. Parasite level dropped by 60%
by day 2 and was no longer detectable by day 3 as shown
in Figure 3.
Adverse events
This combination of Artemisinin-Naphthoquine was
found to be quite safe. Of the 121 patients that were en-
rolled, none had serious adverse event (SAE). Table 3
shows the list of adverse events observed as it applies to
different treatment arms. Weakness and headache were
the most common adverse events reported and were
reported more in the 1400 mg single dose group.
Tolerability
The combination was well tolerated by the study partici-
pants. Biochemistry and haematological parameters did
not deviate significantly from normal values (data not
shown).
Discussion
This study showed an overall 28-day cure rate of 79.3% for
the fixed dose combination of artemisinin-naphthoquine.
It was not possible to perform polymerase chain reaction
(PCR) to confirm the genetic characteristics of the species
reported as treatment failures in this study to determine
whether these were due to recrudescence or actually new
infections. This cure rate is lower than those reported in
other efficacy studies on the same drug, most of which
were between 97% and 98% [9-11,16]. Treatment failures
in all these studies were confirmed with PCR thereby
excluding new infections. It is possible that the failure
to exclude possible new infections in this Nigerian study
with molecular techniques has contributed to the lower
cure rate reported.
Single dose artemisinin-naphthoquine has also been
shown to have an efficacy rate comparable to that of
artemether-lumefantrine [17]. This study did not com-
pare artemisinin- naphthoquine with another ACT, but
Table 2 Outcome of treating uncomplicated malaria with
fixed-dose Artemisinin-Napthoquine combination
Treatment Outcome* Group A (%) Group B(%) Group C (%)
Number enrolled 36 35 50
Number evaluable 34 29 45
28-Day Cure (ACPR) ** 29 (85.3%) 27 (93.1%) 40 (88.9%)
(95% conf. Interval) 68.9 – 95.0 77.2 – 99.2 75.9 – 96.3
Late Parasitological Failure 5 (14.7%) 2 (6.9%) 5 (11.1%)
Lost to follow-up 1 3 3
Withdrawn 1 3 2
*ANOVA showed no significant difference in outcome between treatment
arms (p = 0.880).
**ACPR = Adequate Clinical and Parasitological Response; with no PCR
correction.
Figure 2 Percentage of patients with fever (temperature ≥37.5°C)
following treatment with a fixed combination of
Artemisinin- Naphthoquine.
Figure 3 Percentage of patients with parasitaemia following
treatment with a fixed combination of Artemisinin-
Naphthoquine.
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an earlier study in the same locality showed comparable
cure rates for artemether-lumefantrine (87.0%) and arte-
sunate/amodiaquine (82.5%) [18]. The rapid decrease in
the number of persons with parasitaemia by Day 2 of
follow-up is indicative of the high therapeutic efficacy
characteristic of other forms of ACT already in use. An
adequately powered comparative trial of established for-
mulations of ACT with this agent will be required to es-
tablish non-inferiority or otherwise, as well as
tolerability and adherence to treatment.
The recommended artemisinin-naphthoquine dose for
those aged 15 years and above is a single blister (1,000/
400 mg) comprising eight tablets (125/50 mg). The ex-
ploratory dose-finding assessment performed in this
study showed that the treatment arm that received the
total recommended dose in two split doses of four
tablets (500/200 mg) per dose had a higher 28-day cure
rate than those that received the recommended single
dose regimen without any difference in tolerability. This
observation is limited by the lack of pharmacokinetics
data to adequately investigate bioequivalence.
The unique advantage of artemisinin-naphthoquine is
its simple dosage schedule, a characteristic which is
more likely to be associated with better patient adher-
ence to treatment than ACT regimens that required
multiple dosing schedules [19,20]. The second drug in
this artemisinin combination therapeutic regimen,
naphthoquine has a long elimination half-life and has
not been used widely in this environment as a single
agent for the treatment of P. falciparum malaria and,
therefore, is able to sustain and complete elimination
long after the artemisinin component has waned to
below therapeutic levels [10]. While the use of this com-
bination regimen on naive parasite populations may
achieve high cure rates, there is however significant risk
that widespread single dose use of naphthoquine in this
combination regimen could create sufficient pressure on
the parasites leading to emergence of increasingly less
susceptible mutants and ultimately varying degrees of
parasite resistance [14,21]. This raises significant con-
cern about the continued use of this drug combination
as a single dose regimen among populations resident in
areas with intense perennial transmission where there
is likely to be a rapid increase in the pool of people
with mutant species of P. falciparum. Recent evidence
from clinical evaluation of a large cohort of children
treated with artemether-lumefantrine and artesunate-
amodiaquine showed that these artemisinin-based com-
bination treatments are still highly efficacious in Nigeria
[22]. However, reports of emergence of strains of P falcip-
arum resistant to the artemisinin compound in south-east
Asia calls for greater attention to rationale use of ACT
regimens [23].
In order to prevent or delay the emergence and spread
of P. falciparum resistance to the component drugs of
this potentially beneficial combination regimen (artemi-
nisin-naphthoquine), it would be advisable to use a once
daily regimen for a period long enough to ensure
complete elimination of all susceptible parasites in each
treatment course. In this study, the use of a single-dose
regimen of half the recommended dose was explored
and revealed a fairly good 28-day cure rate but lower
than the rate obtained with the recommended dose. It is
likely that administration of single daily dose of 500/200
mg for three days will achieve high cure rates with much
lower risk of recrudescence than would be the case with
the current practice of single dose of 1,000/400 mg give
only for one day. A well designed trial to test this dosage
option would be of immense public health importance
to avert the likely deterioration of this combination regi-
men from widespread use as single dose regimen.
One of the key elements in any drug development and
evaluation is the issue of safety of the population for
Table 3 Adverse events among patients treated with
Artemisinin-Naphthoquine
Adverse events Frequency (%)
Group A Group B Group C
N = 36 N = 35 N = 50
Weakness 4 (11.1) 1 (2.86) 7 (14.0)
Itching 1 (2.77) 3 (8.57) 0
Joint pains 1 (2.77) 0 1 (2.0)
Tingling sensation in the head 1 (2.77) 0 0
Headache 3 (8.33) 3 (8.57) 10 (20.0)
Body pains 0 1 (2.86) 1 (2.0)
Catarrh 0 1 (2.86) 2 (4.0)
Nausea 0 2 (5.71) 0
Vomiting 0 1 (2.86) 0
Swollen fingers and feet 0 1 (2.86) 0
Bitter taste 1 (2.77) 1 (2.86) 2 (4.0)
Palpitation 0 1 (2.86) 0
Cold 0 1 (2.86) 0
Hearing impairment 0 1 (2.86) 0
Dizziness 1 (2.77) 1 (2.86) 2 (4.0)
Blisters on lips 0 1 (2.86) 0
Loss of appetite 0 0 1 (2.0)
Drowsy 1 (2.77) 0 0
Cough 0 1 (2.86) 1 (2.0)
Throat itch 0 0 1 (2.0)
Heaviness on stomach 0 0 1 (2.0)
Throat pain 0 1 (2.86) 0
Diarrhoea 0 1 (2.86) 0
Waist pain 0 1 (2.86) 0
Meremikwu et al. Malaria Journal 2012, 11:413 Page 6 of 8
http://www.malariajournal.com/content/11/1/413
which the drug is intended. Artemisinin-naphthoquine
was well tolerated and no serious adverse event was
recorded in the study. The commonest adverse events
were weakness and headache which were reported more
in the group that took the recommended dosage. Since
both symptoms could also be caused by malaria, it is not
certain whether these symptoms were due to the drug
alone or caused by the illness itself. This is in keeping
with findings from earlier studies in China that showed
that this drug is safe and well tolerated [9,10,16]. Larger
studies are needed to define the safety and efficacy in
different population including children and pregnant
women.
Conclusion
The artemisinin-naphthoquine combination is a poten-
tially important ACT, which deserves further clinical
evaluation. While the single dose regimen currently
recommended by the developers has a promise for
enhanced patient adherence to treatment, it raises ser-
ious concerns about the likely emergence of resistant
parasite strains to the component drugs. The use of the
formulations in reduced strength over a three-day period
to minimize the risk of emergence of resistant mutants
of P. falciparum is recommended. A well-designed, ad-
equately powered multicentre randomized controlled
trial that meets all GCP requirements will be required to
determine how this potentially important combination
can be put to the best public health use.
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